Abstract
Glaucoma is a neurodegenerative disorder characterized by progressive optic nerve damage and the most common cause for irreversible blindness. Emotional dysregulations are common in glaucoma patients, with high rates of generalized anxiety and depression. Glaucoma leads to pathological changes in the visual pathways of the brain, yet accumulating evidence suggests that the brain changes may reach beyond the visual system. To robustly determine brain morphological alterations in glaucoma and determine a potential overlap with changes observed in anxiety and depression we performed a pre-registered comparative meta-analysis of case control studies examining brain structural integrity in patients with glaucoma, and further determined whether the identified regions are nodes of distinct overarching large-scale networks and overlap with meta-analytic brain structural maps of generalized anxiety disorder (GAD) and major depressive disorder (MDD). Glaucoma patients exhibited robust reductions in gray matter volume in regions contributing to visual processing (lingual gyrus, thalamus), but volumetric reductions extended beyond systems involved in visual processing and also affected the left putamen and insula. Behavioral and functional network level decoding demonstrated distinct large-scale networks and involvement in visual, motivational or affective domains, respectively. Reductions in the insular region involved in pain and affective processes overlapped with alterations previously observed in GAD. Our findings may suggest a tripartite brain model of glaucoma, with changes in visual processing regions such as the lingual gyrus as well as additional alterations in putamen and insular regions meta-analytically associated with motivational or emotional functions, respectively. Together the findings indicate broad neuroanatomical alterations in glaucoma that extend beyond the visual system and may gate further pathological developments.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was supported by the National Natural Science Foundation of China (Grant No. 82271583, Grant No. 32250610208 to BB), and the National Key Research and Development Program of China, Grant No. 2018YFA0701400. Disclaimer: Any opinions, findings, conclusions, or recommendations expressed in this publication do not reflect the views of the Government of the Hong Kong Special Administrative Region or the Innovation and Technology Commission.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
